Neurocrine Biosciences, Inc. (NBIX) Earnings Call Transcript
October 28, 2025
Earnings Call Speaker Segments
Hello, everyone, and a really nice good afternoon to each of you, no matter where you're located. You're listening to the Neurocrine Biosciences call covering our third quarter 2025 earnings. Joining me on this call are Kyle Gano, our Chief Executive Officer, Matt Abernethy, our Chief Financial Officer, Eric Benevich, our Chief Commercial Officer, and Sanjay Keswani, our Chief Medical Officer. On this call, we'll be sharing forward-looking statements; such statements carry certain risks and uncertainties, and what actually happens could differ materially. Please take a look at the risk factors covered in our most recent SEC filings. Following prepared remarks, and consistent with how we normally do things, we'll aim to get to every one of your questions. So with that, I'll hand things over to Kyle.
Thanks, Todd. Hello, everyone, and good afternoon. The results we posted for the third quarter show how well Neurocrine Biosciences has executed, and they demonstrate the power of momentum across our entire enterprise as we keep hitting our goals commercially, clinically, and operationally. On the commercial side, when it comes to INGREZZA, the money we put in recently to grow our sales team and make it easier for patients to get access produced one more record quarter, both for people starting treatment and for overall prescriptions, which underscores the unmet need that persists among patients living with tardive dyskinesia and Huntington's chorea. Turning to CRENESSITY, its impressive launch makes clear its place as a first-in-class treatment, setting a new standard of care for those with classic congenital adrenal hyperplasia, or CAH. We still have a great deal to learn, but the early feedback from the CAH community has us encouraged, as does the chance to create a lasting difference for patients. Both INGREZZA and CRENESSITY have strong momentum, and we expect that ongoing, focused investment in these commercial assets will speed up growth as we move into 2026 and afterward. Within our clinical portfolio, enrollment is progressing steadily in our Phase III trials of osavampator for major depressive disorder and Directlidine for schizophrenia, and I'm glad to say we're still on track to hit our enrollment targets this year. Past those late-stage efforts, we keep moving forward a strong early and mid-stage program that keeps expanding thanks to high-quality preclinical work coming out of Neurocrine Biosciences' internal discovery. Along those lines, I'm delighted to share that we remain on track to reach our R&D productivity targets for the year, namely four new Phase I study initiations and two new Phase II initiations. Moving two medicines that could potentially change the standard of care all the way to their final stage of development, while at the same time pushing innovation in the early and mid-stages, amounts to a record level of productivity for us and puts Neurocrine Biosciences in an exceptionally strong position going forward. Thinking back on my more than 20 years at Neurocrine Biosciences and my just over one year as CEO, I feel enormous pride in what we've achieved. Even so, as we keep evolving, what's ahead inspires me even more. Neurocrine Biosciences stands at the start of a new chapter of lasting long-term growth, powered by our science, our people, and our steadfast dedication to the patients we serve and the veterans who support our mission. With that, I'll hand the call over to Matt.
Appreciate that, Kyle, and welcome, everybody, to this afternoon's call. Neurocrine Biosciences delivered a robust third quarter right across the business, posting $790 million in net product sales — a 28% increase versus the prior year — powered by ongoing gains from both CRENESSITY and INGREZZA. Congratulations to everyone who contributed to how these two medicines performed. CRENESSITY climbed sequentially, going from $53 million in Q2 up to $98 million in Q3, which speaks to solid early uptake and strong persistency; on top of that, reimbursement is now in place for 80% of dispensed prescriptions. What we hear from patients and KOLs continues to be very positive regarding CRENESSITY's efficacy, safety, and tolerability profile. We're eager to keep bringing more patients onto therapy and to further cement CRENESSITY's role as a standard-of-care option for people living with classic congenital adrenal hyperplasia (CAH). INGREZZA's momentum keeps building as well, with Q3 marking our third straight quarter of record new patient starts, generating $687 million in net sales. One thing to keep in mind when you're modeling Q4: the third quarter had the benefit of a 14th ordering week. Setting that ordering dynamic aside, better access combined with our sales force expansion is producing double-digit TRX growth, record NRX, and market share gains across the first nine months of the year; given that momentum and the strength of the tardive dyskinesia (TD) market, we've chosen to move ahead with another sales force expansion, guided by three objectives. First, speed up development of the TD market between now and 2029, reinforcing our position as we manage through the possible effects of the Inflation Reduction Act (IRA). Second, maximize INGREZZA patient share during this window. Third, lay the groundwork for a broader psychiatry portfolio, since we anticipate that one or more of our late-stage clinical programs will produce successful top-line data in 2027. Financially speaking, the greater investment behind both INGREZZA and CRENESSITY will translate into roughly a $150 million rise in SG&A expense in 2026. Naturally, we'll share a more complete financial picture for Neurocrine Biosciences in February of next year, but we wanted to offer this insight at this point. In closing, our capital allocation priorities haven't changed. First, drive revenue growth. Second, advance our R&D programs. Third, enable business development. Fourth, return capital to shareholders. Our top-line growth and financial profile, with more than $2.1 billion in cash, provide the foundation for continued investment in our internal pipeline, which will put Neurocrine Biosciences in position for sustained growth and allow us to bring new, innovative therapies to patients with unmet needs in the years ahead. With that, I'll turn the call over to Eric Benevich, our Chief Commercial Officer. Eric.
Appreciate that, Matt. Our brands had yet another outstanding quarter in Q3. Both INGREZZA and CRENESSITY posted record quarters thanks to the ongoing efforts of our commercial and medical teams, with net sales combined reaching $785 million. Turning first to INGREZZA, the first nine months of 2025 have delivered exceptional performance, which speaks both to the strong clinical profile and to the substantial unmet need that persists for individuals with tardive dyskinesia or Huntington's chorea. Strategic investments made previously to grow the sales force and enhance access have paid off, producing a third straight quarter of record new patient starts and total prescriptions. Right now, out of a population of more than 800,000, we believe roughly only half of those with TD have been diagnosed for their uncontrolled movements, and just about 10% are presently receiving treatment with a VMAT2 inhibitor; with exclusivity running through 2038, a meaningful organic growth opportunity still lies ahead. Our base of INGREZZA prescribers keeps growing, especially within psychiatry, where advanced practice providers like nurse practitioners and physician associates are now responsible for most psychiatric patient care across the United States. To illustrate, the number of INGREZZA prescribers we have today is 30% higher than at this point two years ago. Beyond that, TD prevalence keeps rising alongside wider use of antipsychotic medications; given our strong momentum and the sizable growth opportunity, we've decided to scale up our INGREZZA sales force even further to address this rising demand. Moving forward, we'll expand and restructure our INGREZZA sales organization, creating two dedicated teams: a combined neuropsych team and our existing long-term care team. We'll grow both the neuropsych and LTC teams so we can engage more VMAT2 prescribers than we ever have and strengthen relationships throughout our current prescriber base. As with past expansions, we'll gauge success through growth in new patient starts and total prescriptions — metrics that usually reveal the full effect of field expansion a few quarters after deployment. Expanding the sales teams positions INGREZZA well for 2026 and beyond and will also help prepare us for the expected launches of our next wave of investigational psychiatric medicines now in Phase III development. Now, on to CRENESSITY, where our launch mantra of "So Far, So Great" continues to be well-deserved, with Q3 net sales hitting $98 million in only the third full quarter on the market. In the third quarter, 540 new patients began therapy, which brings the total number of classic congenital adrenal hyperplasia patients on therapy since launch to over 1,600. As we've said from the beginning, this is a new market we're building, so this is a learning launch. Since CRENESSITY is the first therapy developed and approved specifically for patients with classic congenital adrenal hyperplasia, we keep gaining valuable insights into prescriber behavior, patient dynamics, and potential seasonality trends. Adoption has stayed consistent, and although the number of new patients beginning treatment can fluctuate between quarters, the robust persistence and adherence figures we've seen so far make us confident that volumes will keep growing ahead. During Q3, demand from patients tilted slightly toward the pediatric group rather than adults, and it leaned toward females. A variety of endocrinology providers keep writing prescriptions, among them physicians working at multidisciplinary centers of excellence, pediatric endocrinologists, and adult endocrinologists based in the community; regarding payers, reimbursement remains strong. Since launch, 9 out of 10 individuals on CRENESSITY have gotten approval from their insurer, and CRENESSITY is affordable, with 9 out of 10 individuals spending $10 or less each month from their own pocket. The majority pay nothing. Insurance reimbursement hasn't stood in the way of treatment. As the first and only FDA-approved therapy developed specifically for classic congenital adrenal hyperplasia, CRENESSITY offers an appealing blend of efficacy, safety, and tolerability. Our continuing open-label extension trials keep producing valuable information about quality of life, long-term safety, and outcomes that set it apart, which will make an already strong data set even stronger; we estimate that roughly 20,000 people across the U.S. are living with classic congenital adrenal hyperplasia. Given the highly favorable response from the congenital adrenal hyperplasia community and the chance to ease the burden for more individuals with congenital adrenal hyperplasia, we've decided to grow our CRENESSITY sales force as well. As I mentioned in my opening remarks, our commercial execution is going very well. Each of our products is a fast-growing, innovative first-in-disease medicine. Because each holds substantial growth potential, expanding both the INGREZZA and CRENESSITY sales teams was an easy call; this represents an investment in growth and an investment in our future. Both sales force expansions should wrap up entirely by the close of Q1, and we can share more detail on how things are progressing once we're into 2026. These are truly thrilling times at Neurocrine Biosciences as we fulfill our commitment to deliver brave science; with that, I'll turn the call over to our Chief Medical Officer, Dr. Sanjay Keswani.
Thank you, Eric, and good afternoon, everybody. I'll keep my prepared comments short today, since all of our clinical programs are still moving forward as planned. For valbenazine in dyskinetic cerebral palsy, we expect top-line data during the fourth quarter, and the same timing applies to the Phase II proof of concept and dose-finding trial of NBI-770 — our NR2B NAM — when used as an adjunctive therapy in major depressive disorder. Just to remind you, if NBI-770 delivers positive results, that could pave the way for a confirmatory Phase II study, or for kicking off a Phase III trial in major depressive disorder. As Kyle said before, enrollment remains strong in the Phase III trials of osavampator for major depressive disorder and of Directlidine, also known as NBI-568, for schizophrenia, and the remainder of our early to mid-stage pipeline is making good headway too. During today's call, you've heard us bring up our upcoming R&D Day. As my colleagues hinted, we can't wait to host the Wall Street community at our campus in San Diego, where we'll be able to share more specifics about our long-term vision, a great deal of which comes from the excitement surrounding our clinical and early-stage programs, plans, and the progress we've made recently. To give you a slightly fuller picture of the agenda: I'll walk through an overview of our neuropsychiatry programs, highlighting osavampator along with our extensive muscarinic agonist portfolio. After I finish presenting, Dr. John Crystal, a prominent psychiatrist at Yale University, will sit down with me for a moderated Q&A session. Then Jude Onyia, our Chief Scientific Officer, will talk about the R&D transformation work now underway at Neurocrine Biosciences and give a preview of several next-generation programs that we expect to move into clinical development. We hope to see plenty of you there as we reveal the foundation for the next chapter of Neurocrine Biosciences. With that, I'll turn the call back over to Kyle.
Thanks, Sanjay. I think we're ready to take questions now.
Thanks, and nice work on such a solid quarter with impressive commercial results. Our question concerns how patients are behaving and starting on CRENESSITY. Enrollment forms appeared somewhat reduced during Q3 relative to Q2. Did seasonality explain that, or could it reflect an initial launch benefit? Any perspective on those patterns would be useful for us as we try to forecast CRENESSITY over the coming quarters. Thank you.
Hello, Phil, Eric here. Clearly, we feel quite good about how broadly CRENESSITY has been adopted since its launch. Q3 brought 540 new treatment forms, which we view as continued strong uptake consistent with what occurred during the first half of the year. From the outset, we described our expectation as a steady or measured launch, and that is exactly how it has played out so far. Week-to-week adoption stayed very consistent throughout the summer; we do not believe there is any particular quarterly pattern or seasonality at work. The launch remains at an early stage, and only after several cycles pass will we know how things ultimately develop. On the whole, we are very happy with enrollment; having surpassed 1,600 treatment forms cumulatively through Q3, we feel quite optimistic and anticipate continued patient accumulation going forward.
That's genuinely useful. Thanks.
And Phil, I appreciate you getting things started and keeping it to a single question. To keep things fair, we'll only respond to whichever question comes in first.
Thank you, Matt.
Hi there, and thank you very much. I'd like to offer my own congratulations regarding the quarter. My question concerns the IRA, and I hope you'll indulge me because there are two parts to it. I promise you, it truly amounts to a single question. Could you assist us in understanding your approach to the Austedo price that is coming and that we will soon find out about? What kinds of consequences does that carry for Neurocrine Biosciences? Regarding INGREZZA, since discounts have grown and our gross-to-net is now climbing toward the mid-to-high 30% range, does that mean your worst-case outlook has shifted, especially because the small biotech exemption limits the discount to a point that could actually end up lower than where your gross-to-net lands? Thanks so much.
Thank you, Paul. There's quite a bit to address there. Perhaps I'll take the first question and we'll see how much ground we cover. On the subject of Austedo, our perspective is that we will find out about its pricing for both the current and immediate-release versions as well as the XR formulation during November. We expect to get word from CMS around late November, possibly earlier — that's the timeline we're working with at the moment. As for what this could mean for INGREZZA, our current position is that we're still trying to figure out how plans might respond to the pricing of Austedo. What we believe at this stage is that health plans along with PBMs are going to deploy an assortment of tactics both for drugs subject to the IRA and for drugs that aren't facing an IRA-type situation. From our perspective, there are elements we're certain about and elements we aren't. At the end of the day, our position today is that INGREZZA is a remarkably sticky product. When someone begins treatment with INGREZZA, they usually remain on the therapy. That essentially means our focus is on new patient starts across the two-year stretch from 2027 through 2029, which is when our own IRA year arrives. As we get closer to 2027, we'll be pursuing contracting arrangements over roughly the coming 12 to 14 months. Our aim will be to get as many patients as possible taking INGREZZA from now through the close of 2026. Doing so should let us offset any pressure related to NRXs, which so far represent just about 5% of our overall TRX. Looking at it quarter by quarter, that figure is pretty minimal. We'll also be watching for any takeaways from the medications that are subject to negotiation and go into effect next year. The key point, in my view, is that while we'll manage what's within our power regarding INGREZZA, we'll also aim to make the whole company as robust as possible throughout the entire portfolio.
Hi Paul, Eric here. I’d like to jump in and back up a few things. First, we genuinely think formularies can accommodate products that sit alongside MFP; our expectation is that PBMs and health plans won’t all act the same way. A single, one-size-fits-all method isn’t what they’ll adopt. As we mentioned in our prepared remarks, making sure we capture as much patient share as possible as we head into 2027 and afterward is truly critical. That’s exactly what we’re focused on right now, and it’s one reason behind expanding the sales force for INGREZZA.
Hello, everyone. Good afternoon, and thank you for allowing me to ask. My question concerns CRENESSITY. I realize it may be too soon to have this information, but are payers already requiring some specific amount of steroid tapering before they will keep paying for treatment? Regarding the number of days in 3Q compared with 4Q, we are entering the holiday period. What should we expect in terms of a possible seasonal effect on CRENESSITY sales during 4Q? Thank you.
Thank you for asking, Tazeen; Matt here. Apart from the speed and rhythm at which patients come into the clinician's office, we are not truly expecting seasonality. On the seasonality side, nothing. As for reimbursement, having patients reduce steroids to a particular degree has not actually been a condition. What matters is whether they have the underlying disease and whether they are being treated with hydrocortisone. When that is true, reimbursement has gone very smoothly. I want to recognize the team handling this, who advocate for patients. In my view, the insurance providers are able to grasp the value of this new medicine for these patients.
Hello, Phoebe here, filling in for Akash. We appreciate you answering our question. Regarding INGREZZA, since Austedo XR is already considerably pricier than the standard Austedo, have you noticed any shifts in what payers prefer so far? When it comes to the upcoming IRA negotiated pricing, how can you secure INGREZZA's price through 2026 before that announcement happens? Thank you.
Thanks for asking. I believe health plans are recognizing that Teva is partly attempting to steer patients toward larger dose strengths of the deuterated tetrabenazine BID and XR versions. Because that product uses a per milligram pricing model, bigger doses translate into greater revenue for each patient. Health plans are starting to notice this. We've observed instances where health plans would cover, say, the BID version but not the XR. I think given that we've witnessed this dose creep pattern and/or patients moving to the XR version, which costs the plan more, they've become more inclined to work with us. I think that partly accounts for our ability this year, at mid-year, to broaden our formulary coverage. The coverage we currently hold, we anticipate maintaining through 2026. As for setting expectations for the coming year, we ought to expect no less than the same degree of formulary coverage we have today.
For the majority of cases, what we're finding is that we're on equal footing when it comes to formulary coverage. Our aim has consistently been to do things in a way that lets clinicians decide which medicine they'd rather use. That approach will remain our plan moving ahead.
Understood. Thanks a lot.
Excellent. I really appreciate you having my question. I'd like to discuss the 10-Q filing, which mentions a Department of Justice investigation. Is there any detail you can share regarding that? What should our expectations be for upcoming milestones tied to it? Thanks.
Hello, Mohit. Kyle speaking. I'm grateful for this inquiry. Back in August, a CID — that's a civil investigative demand — came to us from the Department of Justice (DOJ), asking for specific paperwork and details tied to the sales, marketing, and promotion of INGREZZA. Naturally, we are collaborating completely with the DOJ. At this point, I believe there isn't a great deal else to add regarding it. We would definitely inform those outside the company once there's substantive news worth sharing about it. The final point I'd make is that an exceptionally strong compliance framework exists within Neurocrine Biosciences, and we regard compliance, along with the duty that accompanies it, with utmost seriousness. Going ahead from here, operations will proceed as normal, since we believe that is the appropriate course. Once more, we'll update everyone as additional details emerge.
Thank you.
Hey there, good afternoon, everyone. Appreciate you taking my question. I wanted to ask about CRENESSITY. What I'm curious about is whether you could walk us through where things stand right now with getting CRENESSITY launched and running at the centers of excellence, and then also how it's going in the community setting, where physicians treat a much smaller number of patients. At this stage, would you say you're at essentially every COE? And do you view that opportunity as existing at the community level? Thanks.
Yeah, so to give a quick recap, our estimate is that roughly 20 centers of excellence exist, and they look after about 15% of the classic CAH patient community. Adoption has now begun at all of the COEs, although the pace differs, I'd say. That, I think, mirrors the varying ways in which they operate, how much bureaucracy there is, how much access there is, and so on. Largely, our sense is that how quickly adoption happens at the COEs mostly comes down to how quickly patients are flowing through. We've also been surprised — quite pleasantly, I'd say — by how fast community endocrinologists who treat the adults have been adopting. As you correctly point out, most of these practices have just one or two patients. That's where you're dealing with a far broader pool of HCPs to reach, and connecting back to what we said in our prepared comments, it's part of why we're expanding our field sales team — to go somewhat deeper into our call universe and to reach some of these practices we haven't yet tapped into.
That's quite useful, thanks.
Hi there, everyone. We really appreciate you fielding our question, and congratulations on the quarter. Might you give us additional detail, and perhaps some numbers, regarding the sales force build-out for the two products, specifically which segments will be called on here for INGREZZA? Would that be psychiatry, neurology, long-term, or, in the case of CRENESSITY, general endos rather than pediatric endos? Many thanks, everyone.
Sure. When it comes to scale, I'd describe it as roughly a 30% rise in our total sales footprint spanning the two products. Clearly, since INGREZZA is the larger product, the bulk of the added headcount will be allocated to INGREZZA. During my prepared remarks, I noted that we would be doing two things: restructuring and expanding. With INGREZZA, what we're essentially doing is merging the psychiatry and neurology teams we already have, then growing headcount in that combined group. Our observation has been that we could serve our psychiatry and neurology customers better — these customers, in many respects, share more similarities than differences — by fielding one cohesive team rather than several separate teams reporting through different structures. In my view, this makes things considerably simpler for us moving forward. The LTC team will remain a standalone unit, and we're growing that group too, since it has been a consistently rapidly growing segment for us. We're eager to broaden our reach among high-potential psych providers and neurology providers through the neuropsych team, and to bring on additional headcount within LTC. For CRENESSITY, the expansion is, of course, smaller in scale. Our current team numbers fewer than 50. This will be a comparatively modest expansion, yet it lets us reach deeper, particularly into those community endocrinology practices, and in the end speed up adoption in classic congenital adrenal hyperplasia (CAH) while helping more patients more quickly.
What this really shows is how strongly we believe in the TD market and in what lies ahead for us. When it comes to Eric and what he's accomplished here, this is likely expansion number four for us. Each time we've made this kind of move, the reaction has been tremendous, and the team has excelled at getting more patients onto therapy. I'd view this spending as plainly aimed at speeding up market development and at getting as many patients as possible on therapy. We consider ourselves lucky to have two excellent medicines for that purpose.
Oh, hey, congratulations on the quarter. We've got a pipeline question about Directlidine. When you consider possible indications outside schizophrenia and bipolar, is Alzheimer's psychosis something you're looking at? Also, are there specific lessons you anticipate learning from the Cobenfy Phase III trial in Alzheimer's once that trial reports, and any possible read across to Directlidine? Thank you.
Thanks so much for asking. As you noted, with 568 or Directlidine, our Phase III program is focused on schizophrenia. A Phase II bipolar mania study began this year. Alzheimer's psychosis is also of great interest to us; our muscarinic portfolio is quite robust, and we will indeed reveal it at R&D Day in December. Regarding which molecule to use, we have many options — M1 preferring, M4 preferring, dual agonists for different indications. Right now, for one of our follow-on molecules, we're considering AD psychosis, since it offers particular advantages when it comes to safety considerations in the elderly. We'll be monitoring BMS's Cobenfy data very closely. From what we understand, their ADEPT Phase III study will report relatively soon. I think there will be lessons learned for the entire field.
Great, thank you.
Hey, thanks. I'd like to return to the topic of the sales force expansion for INGREZZA. You've expanded your sales force multiple times across the years, throughout the commercial life of the product. Given that, when do you believe the commercial organization will reach the right size? And when do you think the DTC spend level will reach the right size? Put differently, when will we begin to see stronger margin expansion tied to the product? Thank you.
Regarding margin expansion, we've achieved enormous progress across the past five years, going from the low 50% range all the way to this year. We ought to land in the low 40% range. Growing revenue to nearly $800 million in this quarter speaks to both the investments and the markets where we compete. When will we be fully right-sized? As you know, we always invest as heavily as we can to pull forward as much revenue as possible in any of these scenarios. We're gaining considerable knowledge as we proceed in the TD market. Broadly, from a margin expansion standpoint, we see the final portion of this decade as a period where we'll keep generating leverage, though perhaps less than what had been expected for 2026. The aim is truly to maximize how many patients are on therapy as we head into the 2027 to 2029 window.
Perhaps I can jump in on that point. I believe we've already discussed this somewhat, but when it comes to TD, the INGREZZA market represents a remarkably strong growth driver for our company. Even though we depend heavily on how the medicine performs, we are still only reaching 10% of the 800,000 patients out there. That's against a background where TD prevalence keeps rising along with the growth rate of antipsychotics, which is 3%- 4% annually, and that is 3%- 4% higher than what we see in the general population. When you combine all of those elements, the count of prescribers goes up each year too. It's growing more quickly than we have grown the sales force across the years; actually, over the past two years, I believe the prescriber base has grown by 30%. Even though we have examined approaches to reach all of these patients and prescribers eventually, our sales organization's present structure is in fact smaller than what some other companies have with products only in schizophrenia; we're happy with our current direction, yet it remains an organization sized appropriately for tardive dyskinesia, and less so for some of the bigger psychiatry indications. I think this move not only assists us with INGREZZA, but, as Eric Benevich mentioned in his opening remarks, positions us quite favorably as we consider osavampator and Directlidine in Phase III and their possible launch in the second half of this decade.
Hi everyone, Luke here filling in for Brian. Regarding the 770 data readout that's coming up, could you share what you're anticipating from those results? And what kind of outcome, in your opinion, would justify running a confirmatory Phase II rather than proceeding straight to pivotal?
The findings from the Phase II trial of NBI-770, which targets our NR2B NAM, should arrive this quarter. To give some background, this Phase II is a fairly small signal-finding effort, enrolling 72 patients in total, split across three active arms plus a placebo group. Most likely, we'd advance into a confirmatory Phase II-B provided the data look encouraging. At this point we aren't ruling out jumping to Phase III; as for the profile we're hoping to observe, efficacy resembling that of esketamine — fairly close to Spravato — would be ideal, yet free from the burden of dissociative side effects that require a 2-hour in-house monitoring window following dosing. We'll find out what the data show later this quarter.
Alright, thank you.
Hey everyone, congratulations on the quarter, and we appreciate you fielding my question. I wanted to ask if you might elaborate a bit further on CRENESSITY's persistence, given that you're now several quarters in. Could you offer anything more granular about what you're observing on that front, and also share the broader KOL perspective regarding patients who began treatment early during the launch, as well as where glucocorticoid equilibration stands now that these patients have been on the drug for many months? Thanks.
Sure — the way I'd put it is that when it comes to CRENESSITY, both persistence and compliance have been really strong. Sure, heading into the launch, we were optimistic that we'd observe this level of overall medication adherence, given what we saw in the double-blind studies and the open-label extensions. Most individuals who began treatment earlier in the year remain on it. Regarding feedback about the reduction of GCs, clearly, all of you have made your doctor calls. You're likely hearing similar things to what we're hearing. People stay on treatment for a certain duration. Physicians are looking for ways to lower androgens, and after that they begin reducing the GCs gradually. This differs somewhat between providers and, in my view, also hinges on each patient's specific circumstances. On the whole, the responses we're getting are quite positive, both regarding control of the disease through androgen reduction and regarding the chance to substantially decrease those GCs toward physiologic or close-to-physiologic concentrations.
Thanks.
Right, Matt. Early in the year, you took a fairly cautious stance on the CRENESSITY launch. My recollection is that your biggest worry was simply reimbursement, and how fast that would get adopted. Clearly, adoption has gone far better than anyone might have anticipated. So how should we now view gross tenets? Looking at the math, they've obviously dropped considerably. Should we expect them to keep falling substantially beyond perhaps Q1 of next year, just given that first quarters tend to be, well, atypical? Over the coming three or four quarters, my sense is they'll just keep declining and step down toward more standard levels for what we'd regard as an orphan product of this kind. Thanks.
Marc, that's entirely reasonable. As far as guidance on gross tenet goes, I'd simply describe it as a gross tenet discount below 20%. For the foreseeable future, that's what we'd expect. Some of the gross tenet dynamics relate to the type of patients involved. Most are commercial, yet we also have a Medicaid population, so the statutory rebate does apply. On the whole, the reimbursement rate, as you noted, exceeds 80%. Per Eric, 9 out of 10 patients have eventually wound up with an adjudicated claim. I'm feeling very confident about where we stand and about achieving a really solid level as we look ahead.
Thank you.
Thanks. Hello, Kyle and the rest of the team. I hope all of you are doing well. I'd like to go back to INGREZZA for a moment — could you talk about how the business breaks down between neurology and psychiatry? Are you putting your attention on psychiatry at the cost of neurology? My recollection is that INGREZZA saw a really solid pickup within neurology, particularly while COVID was going on. What do you have planned when it comes to neurology? Thank you.
Sure. Roughly 15% of the volume we do overall comes from neurology. It's clear that every one of our business segments — neurology, psychiatry, and LTC — has been expanding at a tremendous rate, this year especially. Measured against the others, it has become our smallest segment at this point. We still view it as important, even though the patient opportunity it provides isn't as large as what we get from psychiatry. During my prepared remarks I mentioned that advanced practice providers working in behavioral health represent the segment expanding most quickly. By restructuring and merging our psychiatry and neurology groups, we're directing our resources toward the areas with the greatest growth prospects. From a behavioral standpoint, psychiatry and neurology resemble one another more closely than either does LTC. LTC remains its own unit, and we're growing that team. Meanwhile, our psych and neurology teams are being merged, and then we'll grow that combined team. At the end of the day, our goal is staying aligned with how quickly this market is expanding and pushing forward on bringing in additional patients who are beginning treatment; as we've noted, this represents spending aimed at expansion, and we're quite pleased with the path we're currently following.
I'll just quickly chime in on the neuro side of things. Remember that with INGREZZA, a great deal of the interest we're seeing is coming from the CAH portion of the indication opportunity. When it comes to Huntington's chorea, roughly 30,000 patients exist in the U.S. Around 90% of them have CAH. That figure of 20,000 works out to approximately a 40 to 1 ratio against the tardive dyskinesia patients we currently see. I believe that points to part of the volume flow we're observing in both the neuro and psych areas. That's a factor we keep in mind as we consider additional investments going forward.
Thanks.
Hello, fantastic. Many thanks for fielding the question. Mine concerned capital management. You brought up, clearly, the roughly $150 million rise in SG&A to grow the two sales forces; given that, I'm simply wondering, what's your view regarding keeping the buyback going at that same rate in connection with the fresh $500 million repurchase authorization? Thanks.
Right, so at present we hold $2.1 billion of cash and carry no debt. We are generating profit. What we're doing with the capital today is making top-line growth the priority while also funding R&D at 35%, which is our target range. Naturally, we retain the option to repurchase shares, yet I'd describe our inclination as favoring the use of our capital for business development efforts, currently centered on advancing our own internal initiatives.
Thanks.
Yes, good afternoon, everyone. Perhaps this one is for us. Could you discuss your position when it comes to the proportion of patients who are new-to-category or new-to-class for INGREZZA compared with Austedo? Where might that figure head? Perhaps give some context first — where things stood 12 months ago and where you believe we can get to with the larger sales force across roughly the coming year. Thanks.
Yes, as Matt said, new patient starts, or NRX, in any particular week or month make up a single-digit % of total TRX; they matter enormously given the persistency and compliance those patients show on INGREZZA, and they account for a substantial quantity of likely refills. What we have observed really from the start of the year, with the earlier expansion of our field sales team and the money we have put into broadening formulary coverage, especially within the Medicare segment, is that we are capturing the majority of new patient starts. That is genuinely what is fueling greater total market share from a patient perspective. That is truly a key element of our strategy moving forward, this momentum we are carrying through 2025 into 2026; we want to ensure we sustain it into that pivotal period of 2027 and beyond. The way I would frame it is we are securing the majority of new patient starts now, and we plan to keep doing so going forward.
Thank you.
Hello, and thanks for letting us ask. I’m simply attempting to grasp INGREZZA’s medium-term growth potential, considering the money put into the sales force and the contracting work you’ve completed; in the years prior to any IRA effect, do you think you’re able to expand more quickly than what you steered toward for this year?
The way I’d put it is that during this year, the VMAT2 market is seeing growth in the double digits, while our brand is expanding at a quicker rate than the market; we feel quite good about the trajectory of growth we’re currently on. In fact, as we said before, Q3 amounted to 12% growth versus the prior year. Our aim is to keep that going and bring it into 2026 and afterward, while maximizing our share of patients. We can offer additional detail once we get nearer to our Q4 earnings call and discuss what we expect for 2026. Right now, it appears we will observe a market for VMAT2s that remains strong, robust, and growing, with INGREZZA specifically doing so next year and after.
Hello, and good afternoon. I appreciate you taking my question. My question concerns NBI-770. Since this trial isn't powered for statistical significance, strictly on an absolute basis, what magnitude of change on the primary endpoint are you hoping to observe, considering other agents in this area like Spravato or other psychedelics? And down the road, are you considering testing this in PRD or NDD? Just your present thinking. Thank you.
Hello, Ami. That's a genuinely excellent question. This is a fairly small trial. I'm reluctant to provide an effect size that we would, honestly, deem a success or a failure, since I believe there is an enormous degree of unmet need among this population. As you pointed out, there are possibly two populations we might pursue with NBI-770. The first is adjunctive treatment for major depressive disorder, which is where the program is currently directed. With this mechanism, we obviously could take the Spravato path regarding treatment-resistant depression too. We have a few possibilities. I think we'll make that determination based on the data we get later this quarter.
Thanks.
Good afternoon, and thanks for taking my question. With the Inflation Reduction Act now applying to your competitor, could you share where INGREZZA might feel the biggest effect, whether that's by the kind of patient involved or by the type of prescriber? And on the neuropsych side in particular, with this iteration of your expanded neuropsych sales team, what's the largest number of products you could potentially leverage?
Sure, I'll address the second part of what you asked. Having three products going into psychiatry and long-term care simultaneously is a challenge we'd welcome. Clearly, we're very enthusiastic about the late-stage pipeline, with Directlidine and osavampator both in Phase III trials. As Kyle mentioned in his prepared remarks, we expect data and possible launches in the latter half of this decade. The expansion we're currently undertaking, I believe, positions us well to be able to move and launch with either one of those two products, or possibly both. That said, it isn't enough — so, for instance, if we ultimately get the chance to launch osavampator, we would lack the coverage of primary care, and future primary care prescribers, that we'd need to reach. This takes us partway there, though not all the way. Still, I do think it cuts down on how many changes we'd need to make to get ready for either of those two launches later on.
When it comes to how the IRA and the negotiation affect us, we believe that patients—those already receiving treatment—will remain on therapy throughout this period. You have to consider a 2-year span in which new patients are involved, and the question becomes where they end up going. Much of our current effort is aimed at getting as many patients as possible onto therapy from now until 2027; anything within our power to influence, we will manage in order to boost that figure; we believe we will succeed across that period. Over the next several months, we'll gain additional understanding regarding both what the MFP looks like for osavampator and how payers are behaving; as for the elements within our control, we are doing all that we possibly can. This is an excellent market, and we have an excellent medicine here.
Thanks for fielding my question, Matt. I just want one thing cleared up — that 14-week thing, or the extra week, applies only to INGREZZA, right? And if you're able, could you also say something about the inventory for CRENESSITY? Thanks.
Sure. For the quarter, the inventory build for CRENESSITY came to roughly $7 million. As for the 14 weeks, that's mostly an INGREZZA matter. Figure that it affected the quarter by nearly one whole week. If you're normalizing Q3 to get a sense of how Q4 will trend, I'd say it's reasonable to take that week out, and from that base you can grow going forward.
Hello, and thank you for fielding this. My question concerns CRENESSITY and its new patient starts. From what I recall, 664 were added during the second quarter, while 540 came in during this one. Could there be a warehousing dynamic that is gradually draining from those individuals? Should we anticipate that kind of pattern continuing into the following quarter, and possibly a resumption of growth once the sales force expansion takes effect in the new year? Many thanks.
Sure. What I would say about how adoption looked in Q3 is that it proved highly steady and consistent; our stated expectation was a measured launch, and that is exactly how things have unfolded so far. That said, the pace of adoption overall, in my view, has from the very first day been somewhat faster than we had projected before launching. The wind-down of the adult open-label study gave us a modest boost during Q2, and a number of patients moved late in Q2 onto a commercial drug, which lifted the figures somewhat. On the whole, I would describe the weekly enrollment rate as fairly steady in both Q2 and Q3.
Let me just mention this briefly: the rollout keeps surpassing what we anticipated, and that applies in every area—enrollment forms, persistence, compliance. That's how it has unfolded. In the end, as time goes on, steady uptake of CRENESSITY together with persistency will build volume over time, and that gives us all the confidence we have and need for this to become our next blockbuster here.
Great, thank you all.
Hi everyone, Alex here filling in for Danielle. Appreciate you taking my question. I've got another one about CRENESSITY. I'm just wondering whether any fresh changes are showing up in how new prescriptions split across pediatrics and adults, and also whether there are any patterns around use of the free drug program. Thanks.
Nope, nothing significant has changed on the demographic side. It continues to lean toward younger patients, and mostly toward female patients. That trend emerged roughly a quarter or so after launch, and since then it has remained fairly consistent. Could you remind me what the second part of your question was? My apologies.
Yeah.
Yeah, honestly it's still coming in below our original expectations. The thinking was this: when an insurer hasn't given the go-ahead on a claim within roughly seven days, we could hand out a 30-day supply of CRENESSITY so a patient could get going without much delay. Like I said before, for every 10 patients taking CRENESSITY, 9 have had their prescription cleared by their insurance, so honestly, not a huge number of folks wind up receiving the free drug program.
Okay, thank you very much.
Regarding one of the programs involving valbenazine and dyskinetic cerebral palsy, with the data readout approaching, could you elaborate on what would count as a meaningful shift in the CRIA score within a CP population? In addition, given the expansion of the INGREZZA sales force, how should we view the scale of the opportunity and the overlap with current INGREZZA prescribers? Thank you.
I'll take the first question very briefly. I'm going to move on to the second one. For this group, dyskinetic cerebral palsy, there isn't a validated scale established beforehand. Basically, we are drawing on the UHDRS Huntington's scale. That represents a total maximal CRIA scale. What we assume is that a statistically significant effect on that would be sufficient to be meaningful. Obviously, we will be looking at the full set of data later in this quarter.
Perhaps as a further point on what comes after this. If we had a robust data set, we'd bring it to the agency and make sure there's a route ahead for an NDA filing. Given how large the sales force is now and how it's made up, we'd be fine on that front if it turned out to be an SNDA.
Like I mentioned, Terry, this is my final point to add. There are more people with dyskinetic cerebral palsy than with Huntington’s chorea, yet that group remains considerably below the TD group in size. Should this eventually become an indication, the bigger sales force could reach every likely prescriber.
Many thanks.
Hello. I appreciate your making room for me and answering my question. Once more, congratulations on a solid quarter. From what I noticed, you've restated guidance rather than lifting it. I believe you brought up that additional week in Q3 related to orders. When considering how the Q4 figure might shape up, my sense is the guidance points to something along the lines of a decline, you know, somewhere between mid single digits and roughly flat. Is there anything further we should keep in mind there, such as whether you're anticipating typical seasonal patterns or possibly a bit of built-in caution?
Once you strip out that 14th week, I believe that puts you in a position from which to grow. Looking at how things have gone quarter to quarter across the past several years, the fourth quarter generally delivers sequential improvement somewhere in the range of $15 million- $20 million. What I'd suggest, David, is to adjust Q3 onto a 13-week basis and then consider that kind of growth path. Pricing ought to remain fairly steady. During the third quarter it declined 6%- 7% compared with the prior year. You should expect the same sort of thing in Q4 as well. There's nothing unusual when it comes to pricing.
Hey everyone, I really appreciate you letting me ask something. The 10-K you filed today included a note that the Make America Healthy Again Commission has been sending warning letters about DTC advertisements. You said one of those came in for INGREZZA. Could you describe the contents of that letter and any corrections you may have to make, since that matters quite a bit for the commercial strategy behind that asset? Thanks a lot.
I'll handle this one. Kyle here. A lot of people across the industry, I believe, got a comparable letter containing comparable kinds of material. As a pharma member, I think a solid way to think about it is this: we're dedicated to responsible advertising, it's a significant piece of our business, and we see it as a valuable chance to connect with patients and provide education as well. We'll keep viewing that as an opportunity. To be clear, we carry on doing this responsibly, and we intend to keep at it going forward.
Thanks. I appreciate everyone joining and contributing to such a productive conversation this afternoon. As we look forward, our confidence in where the company is headed and the momentum behind us remains strong; it's our hope that what you've seen today demonstrates that we're carrying out our work with clarity and discipline, growing two commercial franchises in INGREZZA and CRENESSITY, and moving forward a pipeline that is both robust and expanding. We discussed a number of our mid-to-late stage assets today, along with putting resources into the next generation of innovation. That is what Neurocrine Biosciences represents now and going forward. Needless to say, we're eager to connect with many of you at the conferences still ahead this year and, without question, at our R&D Day on December 16. Thanks once more.
That wraps up today's session. We appreciate you taking part. Feel free to leave the call whenever you'd like.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Neurocrine Biosciences, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Neurocrine Biosciences, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.